Evaluation of the Lupus Foundation of America - Rapid Evaluation of Activity in Lupus (LFA-REAL) Clinician Reported Outcome (ClinRO) and Patient Reported Outcome (PRO) in a Primarily Mestizo Population

Manuel Ugarte-Gil¹, Rocío-V. Gamboa-Cárdenas ², Cristina Reátegui-Sokolova ³, Victor Pimentel-Quiroz ⁴, Paola Zeña-Huancas ², Mariela Medina ², Claudia Elera-Fitzcarrald ¹, Samira García ³, Luciana Gil ², Erika Noriega ², Cesar Pastor-Asurza ³, Zoila Rodríguez-Bellido ², Joan Merrill ⁵, Anca Askanase ⁶, Graciela Alarcón ⁷ and Risto Perich-Campos ², ¹Universidad Científica del Sur, Lima, Peru, ²Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Lima, Peru, ³Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, ⁴Hospital Nacional Guillermo Almenara Irigoyen - EsSalud, Lima, Lima, Peru, ⁵Oklahoma Medical Research Foundation, Oklahoma City, ⁶Columbia University, New York, ⁷University of Alabama at Birmingham, Birmingham

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: systemic lupus erythematosus (SLE) and Disease Activity

Session Information

Date: Sunday, November 10, 2019

Title: SLE – Clinical Poster I: Epidemiology & Pathogenesis

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: There are several instruments to measure disease activity in patients with systemic lupus erythematosus (SLE); however, none of them are able to capture all possible clinical events/manifestations. The LFA-REAL ClinRO has been proposed in order to address this problem as it allows the clinician to evaluate every possible manifestation of SLE. Additionally, the LFA-REAL PRO includes a comprehensive patient-reported disease activity measure. The aim of this study was to determine the correlation between both, the LFA-REAL ClinRO and the LFA-REAL PRO, with other disease activity measures.

Methods: A cross-sectional analyses of patients from a single-center cohort was performed. Disease activity measures included were LFA-REAL ClinRO (0-1400), LFA-REAL PRO (0-1200), SLEDAI-2K, clinical SLEDAI-2K and Physician Global Assessment (PGA, 0-100). The correlation between these indices were evaluated with the Pearson correlation. As an alternative analysis, the correlation between the corresponding domains of LFA-REAL PRO and LFA-REAL ClinRO were examined.

Results: One-hundred and sixty-nine patients with SLE, with a mean age of 45.8 (SD: 14.2), 156 (92.3%) were female. The mean (SD) LFA-REAL ClinRO was 23.8 (34.3), the LFA-REAL PRO was 239.6 (187.7), the PGA was 10.0 (14.2), the SLEDAI-2K was 2.4 (3.4) and the clinical SLEDAI-2K was 1.7 (3.0), the SDI was 1.7 (1.5). LFA-REAL ClinRO correlated with LFA-REAL PRO (R=0.192; p=0.012), PGA (R=0.693, p< 0.001), SLEDAI-2K (R=0.688, p< 0.001) and clinical SLEDAI-2K (R=0.705, p< 0.001); the LFA-REAL PRO correlated with PGA (R=0.301, p< 0.001), SLEDAI-2K (R=0.161, p=0.037) and clinical SLEDAI-2K (R=0.167, p=0.030). The correlations between these disease activity measures are depicted in table 1. Additionally, the LFA-REAL PRO rash correlated with the LFA-REAL ClinRO global mucocutaneous involvement (R=0.154, p=0.046) and with the LFA-REAL ClinRO rash (R=0.245, p=0.001); the LFA-REAL PRO global articular correlated with the LFA-REAL ClinRO global musculoskeletal involvement (R=0.346, p< 0.001).

Conclusion: The LFA-REAL ClinRO and the LFA-REAL PRO had a good correlation with other physician-based disease activity measures. These measures need to be evaluated in other cohorts in order to determine their real value for the monitoring of SLE patients.

Table 1 LFA CLinRO PRO

Disclosure: M. Ugarte-Gil, None; R. Gamboa-Cárdenas, None; C. Reátegui-Sokolova, None; V. Pimentel-Quiroz, None; P. Zeña-Huancas, None; M. Medina, None; C. Elera-Fitzcarrald, None; S. García, None; L. Gil, None; E. Noriega, None; C. Pastor-Asurza, None; Z. Rodríguez-Bellido, None; J. Merrill, Xencor, 2; A. Askanase, Xencor, 2; G. Alarcón, None; R. Perich-Campos, None.

To cite this abstract in AMA style:

Ugarte-Gil M, Gamboa-Cárdenas R, Reátegui-Sokolova C, Pimentel-Quiroz V, Zeña-Huancas P, Medina M, Elera-Fitzcarrald C, García S, Gil L, Noriega E, Pastor-Asurza C, Rodríguez-Bellido Z, Merrill J, Askanase A, Alarcón G, Perich-Campos R. Evaluation of the Lupus Foundation of America – Rapid Evaluation of Activity in Lupus (LFA-REAL) Clinician Reported Outcome (ClinRO) and Patient Reported Outcome (PRO) in a Primarily Mestizo Population [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/evaluation-of-the-lupus-foundation-of-america-rapid-evaluation-of-activity-in-lupus-lfa-real-clinician-reported-outcome-clinro-and-patient-reported-outcome-pro-in-a-primarily-mestizo-populatio/. Accessed .

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evaluation-of-the-lupus-foundation-of-america-rapid-evaluation-of-activity-in-lupus-lfa-real-clinician-reported-outcome-clinro-and-patient-reported-outcome-pro-in-a-primarily-mestizo-populatio/